Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin

Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin

Doxorubicin (DOX) is a cytotoxic drug used for the treatment of breast cancer (BC). However, the rapid emergence of resistance toward doxorubicin threatens its clinical application, thus the need for combination therapy. Here, we interrogate the role of Emodin, a chemical compound with tumor inhibit...

Full description

Bibliographic Details
Main Authors: Bo Li, Xin Zhao, Lei Zhang, Wen Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
emodin
AKT1
bioinformatics
DNA repair
breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.588533/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.588533/full

Similar Items